Boehringer sales rise as Jardiance and Ofev thrive
Prescription drug sales were $7.1 billion for the first half of the year
Read More
Author: George Underwood
Biosimilars and key brands drive Pfizer to raise forecasts
Eliquis, Ibrance, Xeljanz and biosimilars help drive profit growth
Read More
EC approves Pfizer’s Herceptin biosimilar
Copycat of blockbuster breast cancer drug is Pfizer’s first oncology biosimilar
Read More
Sanofi profits and sales fall in Q2
US patent losses continue to sting for the company
Read More
Novartis’ migraine drug gets EMA approval
Aimovig becomes Europe’s first treatment specifically designed to prevent migraine
Read More- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
